Cargando…
Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection
It is important to determine the clinical significance of non-human leukocyte antigen (HLA) antibodies and their association with antibody-mediated rejection (ABMR) of kidney allografts. We collected post-transplant sera from 68 ABMR patients, 67 T-cell mediated rejection (TCMR) patients, and 83 con...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131656/ https://www.ncbi.nlm.nih.gov/pubmed/35634584 http://dx.doi.org/10.3389/ti.2022.10099 |
_version_ | 1784713218951741440 |
---|---|
author | Park, Sehoon Yang, Seung-Hee Kim, Jiyeon Cho, Semin Yang, Jaeseok Min, Sang-Il Ha, Jongwon Jeong, Chang Wook Bhoo, Seong Hee Kim, Yong Chul Kim, Dong Ki Oh, Kook-Hwan Joo, Kwon Wook Kim, Yon Su Moon, Kyung Chul Song, Eun Young Lee, Hajeong |
author_facet | Park, Sehoon Yang, Seung-Hee Kim, Jiyeon Cho, Semin Yang, Jaeseok Min, Sang-Il Ha, Jongwon Jeong, Chang Wook Bhoo, Seong Hee Kim, Yong Chul Kim, Dong Ki Oh, Kook-Hwan Joo, Kwon Wook Kim, Yon Su Moon, Kyung Chul Song, Eun Young Lee, Hajeong |
author_sort | Park, Sehoon |
collection | PubMed |
description | It is important to determine the clinical significance of non-human leukocyte antigen (HLA) antibodies and their association with antibody-mediated rejection (ABMR) of kidney allografts. We collected post-transplant sera from 68 ABMR patients, 67 T-cell mediated rejection (TCMR) patients, and 83 control subjects without rejection, and determined the titers of 39 non-HLA antibodies including antibodies for angiotensin II receptor type I and MICA. We compared all these non-HLA antibody titers among the study groups. Then, we investigated their association with the risk of death-censored graft failure in ABMR cases. Among the antibodies evaluated, anti-collagen type I (p = 0.001) and type III (p < 0.001) antibody titers were significantly higher in ABMR cases than in both TCMR cases and no-rejection controls. Both anti-collagen type I [per 1 standard deviation (SD), adjusted odds ratio (OR), 11.72 (2.73–76.30)] and type III [per 1 SD, adjusted OR, 6.22 (1.91–31.75)] antibodies were significantly associated with the presence of ABMR. Among ABMR cases, a higher level of anti-collagen type I [per 1 SD, adjusted hazard ratio (HR), 1.90 (1.32–2.75)] or type III per 1 SD, [adjusted HR, 1.57 (1.15–2.16)] antibody was associated with a higher risk of death-censored graft failure. In conclusion, post-transplant anti-collagen type I and type III antibodies may be novel non-HLA antibodies related to ABMR of kidney allografts. |
format | Online Article Text |
id | pubmed-9131656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91316562022-05-26 Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection Park, Sehoon Yang, Seung-Hee Kim, Jiyeon Cho, Semin Yang, Jaeseok Min, Sang-Il Ha, Jongwon Jeong, Chang Wook Bhoo, Seong Hee Kim, Yong Chul Kim, Dong Ki Oh, Kook-Hwan Joo, Kwon Wook Kim, Yon Su Moon, Kyung Chul Song, Eun Young Lee, Hajeong Transpl Int Health Archive It is important to determine the clinical significance of non-human leukocyte antigen (HLA) antibodies and their association with antibody-mediated rejection (ABMR) of kidney allografts. We collected post-transplant sera from 68 ABMR patients, 67 T-cell mediated rejection (TCMR) patients, and 83 control subjects without rejection, and determined the titers of 39 non-HLA antibodies including antibodies for angiotensin II receptor type I and MICA. We compared all these non-HLA antibody titers among the study groups. Then, we investigated their association with the risk of death-censored graft failure in ABMR cases. Among the antibodies evaluated, anti-collagen type I (p = 0.001) and type III (p < 0.001) antibody titers were significantly higher in ABMR cases than in both TCMR cases and no-rejection controls. Both anti-collagen type I [per 1 standard deviation (SD), adjusted odds ratio (OR), 11.72 (2.73–76.30)] and type III [per 1 SD, adjusted OR, 6.22 (1.91–31.75)] antibodies were significantly associated with the presence of ABMR. Among ABMR cases, a higher level of anti-collagen type I [per 1 SD, adjusted hazard ratio (HR), 1.90 (1.32–2.75)] or type III per 1 SD, [adjusted HR, 1.57 (1.15–2.16)] antibody was associated with a higher risk of death-censored graft failure. In conclusion, post-transplant anti-collagen type I and type III antibodies may be novel non-HLA antibodies related to ABMR of kidney allografts. Frontiers Media S.A. 2022-05-11 /pmc/articles/PMC9131656/ /pubmed/35634584 http://dx.doi.org/10.3389/ti.2022.10099 Text en Copyright © 2022 Park, Yang, Kim, Cho, Yang, Min, Ha, Jeong, Bhoo, Kim, Kim, Oh, Joo, Kim, Moon, Song and Lee. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Health Archive Park, Sehoon Yang, Seung-Hee Kim, Jiyeon Cho, Semin Yang, Jaeseok Min, Sang-Il Ha, Jongwon Jeong, Chang Wook Bhoo, Seong Hee Kim, Yong Chul Kim, Dong Ki Oh, Kook-Hwan Joo, Kwon Wook Kim, Yon Su Moon, Kyung Chul Song, Eun Young Lee, Hajeong Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection |
title | Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection |
title_full | Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection |
title_fullStr | Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection |
title_full_unstemmed | Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection |
title_short | Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection |
title_sort | clinical significances of anti-collagen type i and type iii antibodies in antibody-mediated rejection |
topic | Health Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131656/ https://www.ncbi.nlm.nih.gov/pubmed/35634584 http://dx.doi.org/10.3389/ti.2022.10099 |
work_keys_str_mv | AT parksehoon clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT yangseunghee clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT kimjiyeon clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT chosemin clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT yangjaeseok clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT minsangil clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT hajongwon clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT jeongchangwook clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT bhooseonghee clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT kimyongchul clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT kimdongki clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT ohkookhwan clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT jookwonwook clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT kimyonsu clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT moonkyungchul clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT songeunyoung clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection AT leehajeong clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection |